Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner

Acta Medica Austriaca

Volumn 30, Issue 1, 2003, Pages 22-25

  Bockisch, A ^a   Brandt Mainz, Katja ^a   Gorges R ^a   Muller St ^a   Stattaus, J ^a   Antoch, G ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

FDG; Medullary thyroid cancer; MTC; PET; PET CT

Indexed keywords

CALCITONIN; FLUORODEOXYGLUCOSE F 18;

CALCITONIN BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE SEVERITY; HUMAN; METASTASIS; POSITRON EMISSION TOMOGRAPHY; REVIEW; THYROID MEDULLARY CARCINOMA; TUMOR LOCALIZATION;

FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM METASTASIS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; THYROIDECTOMY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; WHOLE-BODY IRRADIATION;

EID: 0037277902     PISSN: 03038173     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1563-2571.2003.02045.x     Document Type: Review

References (22)

1. Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH, Hör G: Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for imaging of neuroendocrine tumours. Eur J Nucl Med 1998;25: 79-83.
2. Antoch G, Freudenberg L, Stattaus J, Egelhof T, Müller S, Debatin J, Bokkisch A: Optimized scanning for a whole-body PET/CT-scan with oral and intravenous contrast material. In press. AJR.
3. Auffermann W, Clark OH, Thurnber S, Galante M, Higgins CB: Recurrent thyroid carcinoma: characteristics on MR images. Radiology 1988;168: 753-757.
4. Baudin E, Lumbroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P, Roche A, Travagli JP, Parmentier C: Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 1996;37: 912-916.
5. Brandt-Mainz K, Müller SP, Görges R, Saller B, Bockisch A: The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 2000;27: 490-496.
6. Briele B, Hotze A, Kropp J, Bockisch A, Overbeck B, Grünwald F, Kaiser W, Biersack HJ: Vergleich von 201-TI und 99m-Tc- in der Nachsorge des differenzierten Schilddrüsenkarzinoms. Nucl Med 1991;30: 115-124.
7. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, Lange H, Bredow J, Korber C, Grünwald F: Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 2001;28: 1671-1676.
8. Eising EG, Farahati J, Bier D, Knust EJ, Reiners C: Somatostatinrezeptorszintigraphie bei medullärem Schildrüsenkarzinom, GEP-Tumoren und Karzinoiden. Nuklearmedizin 1995;34: 1-7.
9. Engelbach M, Görges R, Forst T, Pfutzner A, Dawood R, Heerdt S, Kunt T, Bockisch A, Beyer J: Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. J Clin Endocrinol Metab 2000;85: 1890-1894.
10. Frank-Raue K, Bihl H, Dörr U, Buhr H, Ziegler R, Raue F: Somatostatin receptor imaging in persistent medullary thyroid carcinoma. Clin Endocrinol 1995;42: 31-37.
11. Gasparoni P, Rubello D, Ferlin G: Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma. J Endocrinol Invest 1997;20: 527-530.
12. Gimm O, Dralle H: C-cell cancer - prevention and treatment. Langenbecks Arch Surg 1999;384: 16-23.
13. Higashi K, Clavo AC, Wahl RL: Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and titrated thymidine uptake. J Nucl Med 1993;34: 41-49.
14. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001;28: 64-71.
15. Juweid M, Sharkey RM, Behr T, Swayne LC, Herskovic T, Pereira M, Rubin AD, Hanley D, Dunn R, Siegel J, Goldenberg DM: Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies. J Nucl Med 1996;37: 905-911.
16. 3)-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20: 716-731.
17. Musholt TJ, Musholt PB, Dehdashti F, Moley JF: Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and ist association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: A clinical and molecular study. Surgery 1997;122: 1049-1061.
18. Reiners C: Imaging methods for medullary thyroid cancer. Recent Results Cancer Res 1992;125: 126-145.
19. Reiners C, Müller SP, Farahati J, Eising EG: SPECT and planar scintigraphy in diagnostic and follow-up of thyroid cancer. Exp Clin Endocrinol 1994;102: 43-50.
20. Ruhlmann J, Vogel J, Bockisch A, Biersack HJ: Metastasen eines medullären Schilddrüsenkarzinoms (follikuläre Variante). Diagnostik und Therapie mit Radio-jod. Dtsch Med Wochenschr 1987;112: 1170-1172.
21. Simeone JF, Daniels GH, Hall DA, McCarthy K, Kopans DB, Butch RJ, Mueller PR, Stark DD, Ferrucci JT Jr., Wang CA: Sonography in the follow-up of 100 patients with thyroid carcinoma. AJR Am J Roentgenol 1987;148: 45-49.
22. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 2002;43: 66-71.